After raising $465M, Kurt von Emster talks about money, biopharma and a new breed of investor: 'The rising tide is pushing everybody into this sector'
If you have to call in to a meeting from anywhere during the pandemic, Carmel-by-the-Sea will do nicely. And Kurt von Emster sounds relaxed and upbeat when we connected earlier in the week to discuss Abingworth’s new fund.
The view is great, and we’re not just talking about surf and sand.
Coming in at $465 million for Abingworth Bioventures 8, their 13th fund, it’s not one of the new, $1 billion-plus unicorn funds we’ve been seeing, with ambitions to radically disrupt old tech, or gearing up to pioneer new fields beyond the cutting edge. But for von Emster and his trans-Atlantic crew, scattered from the Bay Area to Boston/Cambridge and the London home office, its deep international connections are sending in signals from around the globe that the tidal shift in investment capital toward biopharma is lifting all boats.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.